Related Articles
Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation-positive non-small-cell lung cancer
Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer
Tamoxifen in patients with advanced pancreatic adenocarcinoma
INVITRO SYNERGISM BETWEEN A NOVEL AMPHIBIAN OOCYTIC RIBONUCLEASE (ONCONASE(R)) AND TAMOXIFEN, LOVASTATIN AND CISPLATIN, IN HUMAN OVCAR-3 OVARIAN-CARCINOMA CELL-LINE
Survival and prognostic factors in lung cancer patients treated in phase I trials: Japanese experience.